Correction

An error appeared in the October EBGI Summary by Khalifa AA, Ennin E, Duong N, “Oral Vancomycin in Primary Sclerosing Cholangitis: A Biochemical Signal Without Meaningful Clinical Improvement.” The summary reviewed Eaton JE, Clayton MW, Harnois DM, et al. Oral vancomycin is not associated with meaningful changes in liver-related end points among adults with primary sclerosing cholangitis: A randomized, placebo-controlled trial. Am J Gastroenterol. Online ahead of print, Jul 2026.

An earlier version of this summary incorrectly stated that VRE was identified in 8.7% of 69 patients in whom it was assessed in the pooled PSC-IBD literature. This originated from preliminary conference abstract data that was superseeded by the completed study. This statement has been corrected in the current version of the article, which accurately reflects the available evidence.

Additionally, readers are encouraged to read the 2 recently published Correspondence in The American Journal of Gastroenterology which further comment on the trial’s limitations, including patient selection, the ALP normalization endpoint, substantial attrition, and the importance of evaluating intestinal outcomes.

1. Trivedi PJ, Homer V, Hov JR, et al. Letter to the Editor. Am J Gastroenterol 2026; published ahead of print.

2. Buness CW, Wadsworth S, Johnson KM, et al. Letter to the Editor. Am J Gastroenterol 2026; published ahead of print.